Stakeholders: Codevelopment Guide Lacks Clarity On Complementary Dx

November 3, 2016 at 6:38 PM

Stakeholders say FDA's July 15 draft guidance on codevelopment of an in vitro diagnostic with a therapeutic is an important step for advancing personalized medicine, but argue it is crucial the agency also clarify its intentions regarding a new product category called complementary diagnostics.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.